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The functional gastrointestinal disorders and the Rome II
process
Man should strive to have his intestines relaxed all the days of
his life.
Moses Maimonides, AD 1135–1204
A good set of bowels is worth more to a man than any quantity
of brains.
Josh Billings (Henry Wheeler Shaw), AD 1818–1885
Toward a new understanding of the functional
gastrointestinal disorders
For centuries, physicians and historians have recognized
that it is common for maladies to aZict the intestinal tract,
producing symptoms of pain, nausea, vomiting, bloating,
diarrhea, constipation, diYcult passage of food or feces, or
any combination.1 When these symptoms are experienced
as severe, or when they impact on daily life, those aZicted
often attribute the symptoms to an illness and seek medical
care. Traditionally, the physicians caring for these patients
will search for inflammatory, infectious, neoplastic, and
other structural abnormalities to make a specific diagnosis
and oVer specific treatment. Yet as has been common in
medical practice,2 when no structural etiology is found, the
patient is diagnosed as having “functional” symptoms and
is treated symptomatically.
Until recently, the limited scientific knowledge about the
pathophysiology of these symptoms, and the need to diag-
nose by excluding “organic” disease, has led physicians to
feel uncertain about the legitimacy of these symptoms as
bona fide disorders.3 Some have felt insecure in their abil-
ity to manage patients with these conditions, and might
even avoid caring for patients with these complaints. But
over the past two decades, two important processes have
occurred to legitimize these conditions, and to increase
attention toward the research and clinical care of patients
with functional gastrointestinal disorders (FGID). The
first has been a shift in conceptualizing these disorders
from a disease-based, reductionistic model, where the
eVort is directed toward identifying a single underlying
biological etiology, to a more integrated, biopsychosocial
model of illness.4 5 The latter model allows for symptoms to
be understood as physiologically multidetermined (e.g.,
altered motility, enhanced visceral sensitivity, brain–gut
dysregulation) and as modifiable by sociocultural and psy-
chosocial influences. The second change has been the
remarkable growth in investigative techniques that support
this newer conceptualization of brain–gut interactions:
improved motility assessment, the development of the
barostat, imaging of the brain (positron emission tomogra-
phy (PET), functional magnetic resonance imaging
(fMRI)), standardized psychological diagnostic instru-
ments, and the molecular investigation of brain–gut
peptides. As a result, over the past two decades, there has
been a 10-fold increment in Medline citations about irrita-
ble bowel syndrome (IBS), a much larger number of sym-
posia and presentations at national and international
meetings about the FGIDs, and increased eVort by
pharmaceutical companies to identify and test receptor-
active agents to treat these disorders.
These developments built support for an international
eVort to characterize and classify the FGIDs by investiga-
tors and clinicians, pharmaceutical regulatory organiza-
tions, pharmaceutical companies, and federal research
agencies. The Multinational Working Teams to Develop
Diagnostic Criteria for Functional Gastrointestinal Disor-
ders (Rome Committees) began in the mid 1980s as a
series of committees that developed consensus criteria for
over 20 FGIDs and published them in several documents
in Gastroenterology International. These documents were
eventually updated and compiled into a book6 as the Rome
criteria.
In this supplement, we present the second major eVort of
the Rome committees: the update of our growing
knowledge of the FGIDs over the past five years. We
include five articles that detail the FGIDs based on
anatomic region, (esophageal, gastroduodenal, bowel,
biliary, anorectal), and a separate article on pediatric
FGIDs. We also present several articles summarizing
current knowledge on the physiologic (motility/sensation),
basic science (brain–gut), and psychosocial aspects of the
FGIDs, and provide recommendations for the design of
treatment trials for these disorders. In addition, we include
the revised (Rome II) diagnostic criteria for the FGIDs
developed by consensus of experts and based on existing
evidence. Finally, as we enter the new millennium, we offer
recommendations for future studies that will help advance
this growing field.
In this introductory article, I will review the rationale
and limitations of a symptom-based diagnostic (Rome II)
classification system, discuss the process through which the
criteria and consensus information were developed, and
briefly summarize the pathophysiological knowledge that is
evolving about the FGIDs. More detailed information is
provided in the other articles written by the 10 committees.
Rationale for symptom-based diagnostic criteria
The Rome II classification system is based on the premise
that for each disorder there are symptom clusters that
“breed true” across clinical and population groups. While
not completely true (see Qualifications, below), this
presumption provides a framework for identification of
patients for research, which can be modified as new scien-
tific data emerge. The rationale for classifying the FGIDs
into symptom-based subgroups has three bases.7
SITE-SPECIFIC DIFFERENCES
Patients with FGIDs report a wide variety of symptoms
aVecting diVerent regions of the gastrointestinal tract.
These symptoms have in common disturbances in sensory
and/or motor gastrointestinal function, which may overlap
across anatomic regions. However, epidemiological studies
using factor analysis and other methods provide evidence
for the existence of site-specific syndromes.8 9 The clinical
value of separating the functional gastrointestinal symp-
toms into discrete conditions (table 1) is that they can be
reliably diagnosed and more specifically treated. The
FGIDs are classified by anatomic region: esophageal (A),
gastroduodenal (B), bowel (C) and functional abdominal
pain (D), biliary (E), and anorectal (F). Within each ana-
tomic category site, there can be several disorders, each
with specific clinical features. For example, the functional
bowel disorders (C), which include IBS (C1), functional
abdominal bloating (C2), functional constipation (C3),
and functional diarrhea (C4), are all functional bowel dis-
orders attributed to the colon and rectum. Yet IBS, having
pain associated with change in bowel habit, is distinct from
functional diarrhea, which is characterized by loose stools
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and no pain. Presumably, each condition will have different
diagnostic and treatment approaches.
EPIDEMIOLOGICAL DATA
Epidemiological studies show similar prevalences for these
conditions across various studies and populations. The fre-
quencies of bowel symptom patterns reported from
England, France, and China are nearly identical (see
Functional bowel disorders and Functional abdominal
pain). In addition, a factor analysis study using two
community samples10 identified an irritable bowel factor,
and these symptoms were very similar to those developed
from a clinical population of patients with IBS using
discriminant function analysis (Manning criteria).11
NEED FOR DIAGNOSTIC STANDARDS OF CLINICAL CARE AND
RESEARCH
As, by definition, there are no physiological features of
diagnostic value, and because it is symptoms that patients
bring to physicians, the use of a symptom-based classifi-
cation system is rational. Symptom-based criteria, used in
psychiatry (e.g., DSM-IV)12 and rheumatology13 and most
recently the Rome I criteria,6 are becoming increasingly
accepted within gastroenterology. Symptom-based criteria
help guide the diagnostic and treatment approach, reduce
the ordering of unneeded diagnostic tests, and help to
standardize the selection of patients for clinical trials.
QUALIFICATIONS FOR THE USE OF SYMPTOM-BASED CRITERIA
Certain limitations and qualifications need to be
considered.7
Other diseases may coexist that need to be excluded
The high frequency of the FGIDs assures their coexistence
with other (organic) diseases. In fact, IBS and inflamma-
tory bowel disease (IBD) seem to have a greater than
chance association,14 and IBD may even predispose to
IBS.15 Similarly, Helicobacter pylori needs to be excluded
and/or treated among patients with functional dyspepsia.
So, it is necessary to exclude other diseases before a func-
tional gastrointestinal designation can be applied.
Symptoms may overlap with other functional gastrointestinal
disorders
Because diVerent FGIDs may coexist, the criteria need to
allow for hierarchical classification of the FGIDs. For
example, if criteria for both IBS (C1) and functional dys-
pepsia (B1) are fulfilled, then both diagnoses co-exist.
However, if criteria for IBS are fulfilled, but the patient also
has upper gastrointestinal (dyspeptic-like) pain that is
relieved by defecation, then only IBS exists. Also, an
unspecified designation (e.g., unspecified functional bowel
disorder) permits the inclusion of patients with functional
gastrointestinal symptoms who do not meet more specific
categories.
Symptoms must be present for at least 12 weeks over the
previous year
To make a diagnosis of a FGID, symptoms should be
present for at least 12 weeks out of the previous year. There
are certain exceptions—for example, chronic functional
abdominal pain requires six months of symptoms, and cer-
tain pediatric and anorectal disorders require only several
weeks of symptoms. The 12-week qualification is a change
from the Rome I criteria, which only required that
symptoms be present in the previous three months. The
reasons for this change are that FGIDs are conditions that
have a waxing and waning course, and (particularly for
epidemiological surveys) symptoms might not have been
present in the previous three months, but may have existed
prior to that time. The 12 weeks need not be consecutive,
and within each week, symptoms are only required for 1/7
days.
In addition, we recognize the diYculty in translating the
time requirement into a questionnaire. For some purposes,
investigators may choose the last three months as the time
requirement. This choice may be preferred for entry into
clinical trials.
Diagnostic categories do not include psychosocial criteria
Although psychosocial disturbances can aVect the onset,
course and outcome of the FGIDs16 (see Psychosocial
aspects of functional gastrointestinal disorders), they are
not required for diagnosis, as they do not occur in people
with FGID who do not seek health care.17 18
Evidence is determined by clinical consensus and existing
evidence
The proposed diagnostic criteria are derived from the con-
sensus of experts in the field (the committees and their
consultants). Using the Rome I consensus criteria as a
starting point, the committees had to justify all changes for
the Rome II criteria based on existing scientific data, or on
a rational recommendation agreed upon by the committee,
the Coordinating Committee, and the reviewers. Also,
these new criteria will be tested in future studies now
underway, and this will form the basis for future modifica-
tions of the criteria.
The process of developing diagnostic criteria
The process for developing these criteria is a rigorous one.
The consensus process was initiated by Professor Aldo




A3. Functional chest pain of presumed esophageal origin
A4. Functional heartburn
A5. Functional dysphagia









C1. Irritable bowel syndrome
C2. Functional abdominal bloating
C3. Functional constipation
C4. Functional diarrhea
C5. Unspecified functional bowel disorder
D. Functional abdominal pain
D1. Functional abdominal pain syndrome
D2. Unspecified functional abdominal pain
E. Biliary disorders
E1. Gall bladder dysfunction
E2. Sphincter of Oddi dysfunction
F. Anorectal disorders
F1. Functional fecal incontinence
F2. Functional anorectal pain
F2a. Levator ani syndrome
F2b. Proctalgia fugax
F3. Pelvic floor dyssynergia
G. Functional pediatric disorders
G1. Vomiting
G1a. Infant regurgitation
G1b. Infant rumination syndrome
G1c. Cyclic vomiting syndrome
G2. Abdominal pain
G2a. Functional dyspepsia
G2b. Irritable bowel syndrome




G4. Disorders of defecation
G4a. Infant dyschezia
G4b. Functional constipation
G4c. Functional fecal retention
G4d. Non-retentive fecal soiling
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Torsoli for the International Congress of Gastroenterology
in Rome (Roma ’88). Professor Torsoli charged the
committees19 to use a Delphi method20 of decision-making,
which fosters a team eVort to produce consistency in opin-
ion, or consensus (although not necessarily total agree-
ment) for diYcult questions not easily tackled. In 1995, the
Rome II Coordinating Committee took on the responsibil-
ity of carrying these activities further using a rigorous four
year, 10-step process:
(1) The Coordinating Committee identified individuals
with international research and clinical expertise to
chair each of the 10 committees. Each Chair was
charged to develop a manuscript for this supplement
and an expanded manuscript for an upcoming book.
(2) Each Chair, in consultation with the Coordinating
Committee, identified a Co-Chair and recruited an
international panel of up to five additional members
having similar clinical and investigative skills to create
the manuscripts.
(3) Each committee member produced a document in
response to specific assignments given by the Chair
and Co-Chair. Usually the task was to synthesize the
literature regarding the physiological, psychological,
diagnostic, and treatment aspects of a particular
functional disorder or scientific content area.
(4) Each Chair incorporated all documents into a manu-
script that was sent to the entire committee for review.
(5) This process of modification and re-review by the
committee was repeated two more times over a two
year period.
(6) Each committee met for three days in June 1998 to
revise the document, using the Delphi method.20 This
face-to-face meeting led to consensus on the
diagnostic criteria and scientific content.
(7) Each Chair sent the revised document to at least six
outside international experts and to scientists in the
pharmaceutical industry for review and comment.
(8) The committee Chairs responded to the reviewers’
comments either by modifying the manuscripts as
requested, or providing a written response that
addressed the reviewers’ concerns.
(9) The revised manuscripts and the commentaries by
the reviewers and authors were then sent to the
Coordinating Committee who met in November
1998 and again in February 1999 to review these
materials critically, and to submit critiques back to
the authors.
(10) Finally, when the document was completed, all
members signed oV their approval before it was
returned back to the Coordinating Committee for a
final check on content and style prior to submission
for publication.
Observations on the functional gastrointestinal
disorders
In proposing the diagnostic groupings listed in table 1, we
recognize that, despite diVerences in location and symptom
features, they share common features with regard to their
motor and sensory physiology, central nervous system
(CNS) relationships, and the approach to patient care.
What follows are general observations and guidelines for
these disorders.
ABNORMAL MOTILITY
It is well recognized that vomiting, diarrhea, acute
abdominal pain, incontinence, and many other gastro-
intestinal symptoms are generated by disturbed gastro-
intestinal motility. Furthermore, in healthy subjects, strong
emotion or environmental stress can lead to increased
motility in the esophagus, stomach, small intestine, and
colon. The FGIDs are characterized by having an even
greater motility response to stressors (psychological or
physiological) when compared with responses in normal
subjects; candidate electrical activity markers have been
proposed which may facilitate these responses.21 However,
these motor responses are only partially correlated with
symptoms and are not suYcient to explain reports of
chronic or recurrent abdominal pain.
VISCERAL HYPERSENSITIVITY
The poor association of pain with gastrointestinal motility
in many of the FGIDs (e.g., functional chest pain of
presumed esophageal origin (A3), functional dyspepsia
(B1), IBS (C1), functional abdominal pain (D)), is
explained by more recent studies relating to abnormalities
in visceral sensation.22 These patients may have a lower
pain threshold when tested with balloon distension of the
bowel (visceral hyperalgesia), or they may have increased
sensitivity even to normal intestinal function (e.g., allody-
nia), and there may be an increased or unusual area of
somatic referral of visceral pain. It is not yet clear whether
visceral hypersensitivity in the FGIDs relates to (a) altered
receptor sensitivity at the viscus itself, (b) increased
excitability of the spinal cord dorsal horn neurons, or (c)
altered central modulation of sensation.21
Another recent observation is that visceral hypersensitiv-
ity may be induced (stimulus hyperalgesia) in response to
rectal or colonic distension in normal subjects23 and to a
greater degree in people with IBS.24 So the pain of an
FGID may relate to sensitization resulting from chronic
motor hyperactivity (e.g., discrete clustered contractions),
gastrointestinal infection (e.g., H pylori for functional dys-
pepsia and enteric infections for IBS (see later) or trauma/
injury to the viscera).
INFLAMMATION
Certain investigators have proposed that increased inflam-
mation in the enteric mucosa or neural plexi may contrib-
ute to symptom development.25 This may occur by periph-
eral sensitization (see earlier), and/or hypermotility
activated by induction of mucosal inflammatory
cytokines.26 This hypothesis follows clinical observations
that about one-third of patients with IBS report that their
symptoms began after an acute enteric infection, and also,
one-third of patients presenting with an acute enteric
infection will go on to develop IBS-like symptoms.27 28
BRAIN–GUT INTERACTIONS
To bring these observations together, we emphasize a more
integrative biopsychosocial understanding of these symp-
toms as being generated by a combination of intestinal
motor, sensory, and CNS activity—the brain–gut axis.29
Thus, extrinsic (vision, smell, etc.) or enteroceptive (emo-
tion, thought) information have, by nature of their neural
connections from higher centers, the capability to aVect
gastrointestinal sensation, motility, secretion, and inflam-
mation. Conversely, viscerotopic eVects (e.g., nociception)
reciprocally aVect central pain perception, mood, and
behavior. For example, spontaneously induced contrac-
tions of the colon in rats lead to activation of the locus
coeruleus in the pons, an area closely connected to pain
and emotional centers in the brain.30 Conversely, increased
arousal or anxiety is associated with a decrease in the
frequency of migrating motor complex activity of the small
bowel.31
Brain–gut interactions may also influence postinfectious
IBS. In a study of patients admitted for acute gastroenteritis,
23% developed IBS-like symptoms three months later.
When comparing those who developed IBS symptoms with
those who did not: (1) psychosocial diYculties (life stress
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and hypochondriasis) predicted who would go on to develop
IBS symptoms; (2) altered gut physiology (abnormal motil-
ity and visceral hypersensitivity) was present at three months
in both groups (i.e., with or without symptoms); and (3)
increased inflammatory cells were present only in the group
with IBS symptoms.28 So although the acute infection led to
physiological disturbances in the gut (altered sensation and
motility), it seems that the psychological distress contributed
to the later experience of the symptoms. The stress may per-
petuate IBS symptoms by CNS facilitation of inflammation,
via disruption of the hypothalamic–pituitary–adrenal/
cytokine stress pathway.32 33
It is now possible to study the brain physiology of
patients with FGIDs using PET, fMRI, and related imag-
ing modalities.34 These studies may help us to understand
the role of the CNS in modulating visceral pain and motil-
ity. They may also provide a marker for studying responses
to psychological treatments or psychopharmacological
agents, as has been shown in analogous studies of psychiat-
ric disorders. It was recently reported that depressed
patients with more active anterior cingulate gyrus activity
on PET imaging were more likely to respond to
antidepressants.35
BRAIN–GUT PEPTIDES
A treatment approach consistent with the concept of brain–
gut dysfunction is likely to involve the neuropeptides and
receptors present in the enteric and central nervous systems.
Putative agents include primarily 5-hydroxytryptamine and
its congeners, the enkephalins and opioid agonists, sub-
stance P, calcitonin gene related polypeptide, and chole-
cystokinin, among others. These neuropeptides have inte-
grated activities on gastrointestinal function and human
behavior depending upon their location. Ongoing phase II
and III pharmacological treatment trials using agents active
at these receptor sites are addressing the diverse, but
interconnected symptoms of pain, bowel dysfunction, and
psychosocial distress so commonly associated with the
FGIDs. The information gained from these studies may
increase our understanding of these conditions, as well as
possibly provide more eVective treatment for patients with
these conditions.
PSYCHOSOCIAL FACTORS
Although psychosocial factors do not define these
disorders, and are not required for diagnosis (see later),
they are important modulators of the patient’s experience
and behavior, and ultimately, the clinical outcome.
Research on the psychosocial aspects of patients with
FGIDs yields three general observations:
+ Psychological stress exacerbates gastrointestinal symp-
toms. Psychological stress or one’s emotional responses
to stress can aVect gastrointestinal function and produce
symptoms in healthy subjects, but does so to a greater
degree in patients with FGIDs.36
+ Psychological disturbances modify the experience of ill-
ness and illness behaviors such as health care seeking.
Although patients with FGIDs show greater psychologi-
cal disturbance than otherwise healthy subjects and
patients with medical disease (see Psychosocial aspects
of functional gastrointestinal disorders), the data are
drawn from patients seen at referral centers; among
non-health care seekers, such disturbances are no
diVerent than in the general population.17 18 So psycho-
social factors modulate illness experience and behaviors
such as health care seeking. This explains findings asso-
ciated with psychosocial trauma (e.g., history of sexual
or physical abuse) which is found to be more common in
referral centers than in primary care, may lower pain
threshold and symptom reporting, and is associated
with a poorer clinical outcome.37
+ An FGID may have psychosocial consequences. Any
chronic illness has psychosocial consequences on one’s
general well-being, daily function status, one’s sense of
control over the symptoms, and the implications of the
illness in terms of future functioning at work and at
home. This is understood in terms of one’s health-
related quality of life (HRQOL). Several new HRQOL
instruments have been developed to evaluate patients
with FGIDs (see Psychosocial aspects of functional
gastrointestinal disorders and Design of treatment trials
for the functional gastrointestinal disorders).
A biopsychosocial conceptualization
As indicated by the findings summarized in the previous
section, the links among psychosocial and physiological
factors are essential for a full understanding of the mecha-
nisms and varying presentations of the FGIDs. Figure 1
conceptualizes this biopsychosocial understanding of the
relationship between psychosocial and physiological fac-
tors with functional gastrointestinal symptoms and the
clinical outcome. Early in life, genetics and environmental
influences (e.g., family attitudes toward bowel training or
illness in general, major loss or abuse history, or exposure
to an infection) may aVect one’s psychosocial development
(susceptibility to life stress, psychological state, coping
skills, development of social support) or the development
of gut dysfunction (abnormal motility or visceral hypersen-
sitivity). In addition, the presence and nature of a FGID is
determined by the interaction of psychosocial factors and
altered physiology via the brain–gut axis. So, one individual
aZicted with a bowel disorder, but with no psychosocial
disturbances and good coping skills and social support,
may not experience the symptoms as distressing enough to
seek medical care. Another, having co-existent psychoso-
cial disturbance, high life stress, and poor social support,
may experience the symptoms as severe and unmanage-
able, may see physicians frequently, and have a generally
poor outcome.
Based on the observations presented, it is no longer
rational to try to discriminate whether physiological or
psychologic factors produce pain or other bowel symp-
toms, dysmotility, or inflammation. Instead, the FGIDs
seem to be understood in terms of dysregulation of brain–
gut function, and the task is to determine the degree to
which each is operative and remediable.
Concluding comments
It is with great pleasure and anticipation that we introduce
this supplement on the functional gastrointestinal disor-
ders, containing information on over two dozen adult and
Figure 1 A biopsychosocial conceptualization of the pathogenesis and
clinical expression of the functional gastrointestinal disorders (FGID).
CNS, central nervous system; ENS, enteric nervous system.
FGID—Conceptual model
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pediatric FGIDs, as well as supplementary information on
the basic, physiologic and psychosocial aspects of these
conditions. We hope that the information will make a dif-
ference in increasing awareness and knowledge relating to
the diagnosis and care of patients with FGIDs. This
supplement, and the book to follow (Rome II: The
Functional Gastrointestinal Disorders published by Degnon
Associates, 2000), which will contain more detailed infor-
mation, are the culmination of four years of eVort by over
60 internationally recognized investigators in the field. For
further information, contact www.romecriteria.org.
As new scientific data about these disorders accumulate,
there will be a need to revise the diagnostic criteria and the
information provided relating to the pathophysiology and
treatment of these conditions. Therefore, we have set up a
process for validation studies and other future activities of
the Rome Committees that will permit ongoing review and
modification of our current recommendations.
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